Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Gi Hoon Nam; Yoonjeong Choi; Gi Beom Kim; Seohyun Kim; Seong A. Kim; In San Kim

doi:10.1002/adma.202002440

Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Gi Hoon Nam, Yoonjeong Choi, Gi Beom Kim, Seohyun Kim, Seong A. Kim, In San Kim

Research output: Contribution to journal › Review article › peer-review

209 Citations (Scopus)

Abstract

Exosomes are a class of extracellular vesicles of around 100 nm in diameter that are secreted by most cells and contain various bioactive molecules reflecting their cellular origin and mediate intercellular communication. Studies of these exosomal features in tumor pathogenesis have led to the development of therapeutic and diagnostic approaches using exosomes for cancer therapy. Exosomes have many advantages for conveying therapeutic agents such as small interfering RNAs, microRNAs, membrane-associated proteins, and chemotherapeutic compounds; thus, they are considered a prime candidate as a delivery tool for cancer treatment. Since exosomes also provide an optimal microenvironment for the effective function of immunomodulatory factors, exosomes harboring bioactive molecules have been bioengineered as cancer immunotherapies that can effectively activate each stage of the cancer immunity cycle to successfully elicit cancer-specific immunity. This review discusses the advantages of exosomes for treating cancer and the challenges that must be overcome for their successful clinical development.

Original language	English
Article number	2002440
Journal	Advanced Materials
Volume	32
Issue number	51
DOIs	https://doi.org/10.1002/adma.202002440
Publication status	Published - 2020 Dec 22

Bibliographical note

Funding Information:
G.-H.N. and Y.C. contributed equally to this work. This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT, 2017R1A3B1023418), by the KU-KIST School Project, and by the KIST Institutional Program. The authors would like to thank Wiley Editing Services for English language editing.

Funding Information:
G.‐H.N. and Y.C. contributed equally to this work. This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT, 2017R1A3B1023418), by the KU‐KIST School Project, and by the KIST Institutional Program. The authors would like to thank Wiley Editing Services for English language editing.

Publisher Copyright:
© 2020 The Authors. Published by Wiley-VCH GmbH

Keywords

cancer therapeutics
characterization and clinical-grade exosomes
exosomes
extracellular vesicles
immunotherapy

ASJC Scopus subject areas

General Materials Science
Mechanics of Materials
Mechanical Engineering

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/adma.202002440

Cite this

@article{55161532e24c4836b5ff89439b1e9d74,

title = "Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy",

abstract = "Exosomes are a class of extracellular vesicles of around 100 nm in diameter that are secreted by most cells and contain various bioactive molecules reflecting their cellular origin and mediate intercellular communication. Studies of these exosomal features in tumor pathogenesis have led to the development of therapeutic and diagnostic approaches using exosomes for cancer therapy. Exosomes have many advantages for conveying therapeutic agents such as small interfering RNAs, microRNAs, membrane-associated proteins, and chemotherapeutic compounds; thus, they are considered a prime candidate as a delivery tool for cancer treatment. Since exosomes also provide an optimal microenvironment for the effective function of immunomodulatory factors, exosomes harboring bioactive molecules have been bioengineered as cancer immunotherapies that can effectively activate each stage of the cancer immunity cycle to successfully elicit cancer-specific immunity. This review discusses the advantages of exosomes for treating cancer and the challenges that must be overcome for their successful clinical development.",

keywords = "cancer therapeutics, characterization and clinical-grade exosomes, exosomes, extracellular vesicles, immunotherapy",

author = "Nam, {Gi Hoon} and Yoonjeong Choi and Kim, {Gi Beom} and Seohyun Kim and Kim, {Seong A.} and Kim, {In San}",

note = "Funding Information: G.-H.N. and Y.C. contributed equally to this work. This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT, 2017R1A3B1023418), by the KU-KIST School Project, and by the KIST Institutional Program. The authors would like to thank Wiley Editing Services for English language editing. Funding Information: G.‐H.N. and Y.C. contributed equally to this work. This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT, 2017R1A3B1023418), by the KU‐KIST School Project, and by the KIST Institutional Program. The authors would like to thank Wiley Editing Services for English language editing. Publisher Copyright: {\textcopyright} 2020 The Authors. Published by Wiley-VCH GmbH",

year = "2020",

month = dec,

day = "22",

doi = "10.1002/adma.202002440",

language = "English",

volume = "32",

journal = "Advanced Materials",

issn = "0935-9648",

publisher = "Wiley-Blackwell",

number = "51",

}

TY - JOUR

T1 - Emerging Prospects of Exosomes for Cancer Treatment

T2 - From Conventional Therapy to Immunotherapy

AU - Nam, Gi Hoon

AU - Choi, Yoonjeong

AU - Kim, Gi Beom

AU - Kim, Seohyun

AU - Kim, Seong A.

AU - Kim, In San

N1 - Funding Information: G.-H.N. and Y.C. contributed equally to this work. This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT, 2017R1A3B1023418), by the KU-KIST School Project, and by the KIST Institutional Program. The authors would like to thank Wiley Editing Services for English language editing. Funding Information: G.‐H.N. and Y.C. contributed equally to this work. This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT, 2017R1A3B1023418), by the KU‐KIST School Project, and by the KIST Institutional Program. The authors would like to thank Wiley Editing Services for English language editing. Publisher Copyright: © 2020 The Authors. Published by Wiley-VCH GmbH

PY - 2020/12/22

Y1 - 2020/12/22

N2 - Exosomes are a class of extracellular vesicles of around 100 nm in diameter that are secreted by most cells and contain various bioactive molecules reflecting their cellular origin and mediate intercellular communication. Studies of these exosomal features in tumor pathogenesis have led to the development of therapeutic and diagnostic approaches using exosomes for cancer therapy. Exosomes have many advantages for conveying therapeutic agents such as small interfering RNAs, microRNAs, membrane-associated proteins, and chemotherapeutic compounds; thus, they are considered a prime candidate as a delivery tool for cancer treatment. Since exosomes also provide an optimal microenvironment for the effective function of immunomodulatory factors, exosomes harboring bioactive molecules have been bioengineered as cancer immunotherapies that can effectively activate each stage of the cancer immunity cycle to successfully elicit cancer-specific immunity. This review discusses the advantages of exosomes for treating cancer and the challenges that must be overcome for their successful clinical development.

AB - Exosomes are a class of extracellular vesicles of around 100 nm in diameter that are secreted by most cells and contain various bioactive molecules reflecting their cellular origin and mediate intercellular communication. Studies of these exosomal features in tumor pathogenesis have led to the development of therapeutic and diagnostic approaches using exosomes for cancer therapy. Exosomes have many advantages for conveying therapeutic agents such as small interfering RNAs, microRNAs, membrane-associated proteins, and chemotherapeutic compounds; thus, they are considered a prime candidate as a delivery tool for cancer treatment. Since exosomes also provide an optimal microenvironment for the effective function of immunomodulatory factors, exosomes harboring bioactive molecules have been bioengineered as cancer immunotherapies that can effectively activate each stage of the cancer immunity cycle to successfully elicit cancer-specific immunity. This review discusses the advantages of exosomes for treating cancer and the challenges that must be overcome for their successful clinical development.

KW - cancer therapeutics

KW - characterization and clinical-grade exosomes

KW - exosomes

KW - extracellular vesicles

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85092066002&partnerID=8YFLogxK

U2 - 10.1002/adma.202002440

DO - 10.1002/adma.202002440

M3 - Review article

C2 - 33015883

AN - SCOPUS:85092066002

SN - 0935-9648

VL - 32

JO - Advanced Materials

JF - Advanced Materials

IS - 51

M1 - 2002440

ER -

Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this